{"title":"[Allergen-induced bronchoconstriction in asthma: antagonistic effect of a synthetic anticholinergic drug (author's transl)].","authors":"J Orehek, P Gayrard, C Grimaud, J Charpin","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>In ten allergic patients, the effect of inhaltion of increasing quantities of grass pollen on specific airways resistance (SRaw, measured by plethysmography) was estimated after preliminary inhalation of a placebo and of a synthetic anticholinergic drug (SCH 10000). After placebo, the inhalation of grass pollen induced in all cases a bronchoconstriction (mean increase of SRaw : 170 %). After SCH 1000, and for the same quantity of pollen inhaled, seven patients were entirely protected against the bronchoconstrictor effect of the allergen ; for the whole group, the observed bronchoconstriction was significantly lower (p less than 0.01, mean increase of SRaw : 60 %). The possible mechanisms of this protection are discussed. The results suggest that SCH 1000 could be used as a preventive drug in pollinic asthma.</p>","PeriodicalId":75638,"journal":{"name":"Bulletin de physio-pathologie respiratoire","volume":"11 2","pages":"193-201"},"PeriodicalIF":0.0000,"publicationDate":"1975-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin de physio-pathologie respiratoire","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
In ten allergic patients, the effect of inhaltion of increasing quantities of grass pollen on specific airways resistance (SRaw, measured by plethysmography) was estimated after preliminary inhalation of a placebo and of a synthetic anticholinergic drug (SCH 10000). After placebo, the inhalation of grass pollen induced in all cases a bronchoconstriction (mean increase of SRaw : 170 %). After SCH 1000, and for the same quantity of pollen inhaled, seven patients were entirely protected against the bronchoconstrictor effect of the allergen ; for the whole group, the observed bronchoconstriction was significantly lower (p less than 0.01, mean increase of SRaw : 60 %). The possible mechanisms of this protection are discussed. The results suggest that SCH 1000 could be used as a preventive drug in pollinic asthma.